A recently developed reversible MAO-B inhibitor also rescues memory and learning deficits in the APP/PS1 mouse model of AD, which also provides a strong argument for investigating MAO-B inhibitors as AD therapeutics [15]. This evidence concerns the gene APP and Alzheimer disease.